Difficulty of lifetime diagnosis of Hodgkin lymphoma: Case report

Hodgkin’s lymphoma (HL) is a rare B-cell lymphoid malignancy. Its clinical presentation is nonspecific and highly variable, which can complicate differential diagnosis. Differential diagnosis of HL includes infectious, autoimmune, and other malignant conditions. With timely treatment, mortality from this disease is extremely low. However, delays in therapy can lead to a worse prognosis and even death. The main symptom of HL is gradually developing asymmetric painless lymphadenopathy, which can remain asymptomatic for a long time. Ninety percent of young adults have lymph node involvement above the diaphragm, while only 10% have lymphoid organ involvement below the diaphragm. This clinical case of HL in a 48-year-old woman demonstrates the difficulties of antemortem diagnosis of this disease. The leading symptoms of the disease were fever and lymphadenopathy of the deep lymph nodes, which were determined by imaging studies. Overestimation of the results of imaging diagnostics, a low initial suspicion for malignancy, the absence of peripheral lymphadenopathy, and, consequently, difficulties in biopsy of the enlarged lymph nodes, along with the addition of coronavirus infection, prevented verification of the diagnosis during life and led to a fatal outcome. This article presents the stages of differential diagnosis and the impact of coronavirus infection on the course of the disease. This clinical case demonstrates the difficulties in interpreting the results of additional imaging diagnostics in HL and the lack of awareness among physicians of the clinical manifestations and diagnostic criteria of this disease.

1. Demina EA, Tumyan GS, Moiseeva TN, Mikhailova NB, Myakova NV, Rumyantsev AG et al. Hodgkin Lymphoma. Clinical recommendations. Journal of Modern Oncology. 2020;22(2):6–33. (In Russ.) https://doi.org/10.26442/18151434.2020.2.200132.

2. Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhen Z et al. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J Hematol Oncol. 2019;12:107. https://doi.org/10.1186/s13045-019-0799-1.

3. Huang J, Pang WS, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W et al.; NCD Global Health Research Group, Association of Pacific Rim Universities (APRU). Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol. 2022;15(1):57. https://doi.org/10.1186/s13045-022-01281-9.

4. Aslani A, Morsali S, Mousavi SE, Choupani S, Nejadghaderi ZY, Nejadghaderi SA. Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020. Sci Rep. 2024;14:20500. https://doi.org/10.1038/s41598-024-69975-3.

5. Munir F, Hardit V, Sheikh IN, AlQahtani S, He J, Cuglievan B et al. Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int J Mol Sci. 2023;24(12):10095. https://doi.org/10.3390/ijms241210095.

6. Демина ЕА. Руководство по лечению лимфомы Ходжкина. 2-е изд. М.: «Ре Медиа»; 2021. 96 с.

7. Ansell SM. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(11):1478–1488. https://doi.org/10.1002/ajh.26717.

8. Shanbhang S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132. https://doi.org/10.3322/caac.21438.

9. Lamb МJE, Roman E, Howell DA, Kane E, Bagguley T, Burton C. Hodgkin lymphoma detection and survival: findings from the Haematological Malignancy Research Network. BJGP. 2019;3(4):bjgpopen19X101668. https://doi.org/10.3399/bjgpopen19X101668.

10. Howell DA, Hart RI, Smith AG, Macleod U, Patmore R, Roman E. Disease-related factors affecting timely lymphoma diagnosis: a qualitative study exploring patient experiences. BJGP. 2019;69(679):e134–e145. https://doi.org/10.3399/bjgp19X701009.

11. Al-Juhaishi T, Ahmed S. Management of limited-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2023;(1):500–509. https://doi.org/10.1182/hematology.2023000511.

12. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM et al. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. JNCCN. 2020;18(6):775–781. https://doi.org/10.6004/jnccn.2020.0026.

13. Tiis RP, Osipova LP. Interleukin-6: it’s role in the organism, genetic polymorphism and significance in certain diseases (literature review). Medical Genetics.2022;21(1):14–27. (In Russ.) https://doi.org/10.25557/2073-7998.2022.01.14-27.

14. Danilenko AA, Falaleeva NA, Shakhtarina SV. History of the role of bone marrow biopsy in the staging system of classical Hodgkin’s lymphoma and a modern view in the era of PET-CT (literature review). Clinical Oncohematology. 2023;16(4):351–360. https://doi.org/10.21320/2500-2139-2023-16-4-351-360.

15. Kanoun S, Rossi C, Casasnovas O. [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives. Cancers. 2018;10(5):145. https://doi.org/10.3390/cancers10050145.